Clinical

Dataset Information

0

A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancer


ABSTRACT: Interventions: Panitumumab with irinotecan/S-1(IRIS) S-1,80-120mg/body for twice daily 14 consecutive days followed by 2 weeks rest combined with intravenous CPT-11 100mg/m^2 and P-mab 6mg/kg(weight) given on day1,15 every 4 weeks until disease progression or unmanageable toxicity. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Kras Wild Type Metastatic Colorectal Cancer

PROVIDER: 2623902 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2627635 | ecrin-mdr-crc
| 2623112 | ecrin-mdr-crc
| PRJNA807619 | ENA
| PRJNA807620 | ENA
| PRJNA765846 | ENA
2021-08-18 | GSE121786 | GEO
| PRJNA445912 | ENA
| PRJNA635730 | ENA
| PRJNA831998 | ENA
| PRJNA170471 | ENA